Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Jonathan GreinNorio OhmagariDaniel ShinGeorge DiazErika AspergesAntonella CastagnaTorsten FeldtGary GreenMargaret L GreenFrançois-Xavier LescureEmanuele NicastriRentaro OdaKikuo YoEugenia Quiros-RoldanAlex StudemeisterJohn RedinskiSeema AhmedJorge BernettDaniel ChelliahDanny ChenShingo ChiharaStuart H CohenJennifer CunninghamAntonella D'Arminio MonforteSaad IsmailHideaki KatoGiuseppe LapadulaErwan L'HerToshitaka MaenoSumit MajumderMarco MassariMarta Mora-RilloYoshikazu MutohDuc NguyenEwa VerweijAlexander ZoufalyAnu O OsinusiAdam DeZureYang ZhaoLijie ZhongAnand ChokkalingamEmon ElboudwarejLaura TelepLeighann TimbsIlana HenneScott SellersHuyen CaoSusanna K TanLucinda WinterbournePolly DesaiRobertino MeraAnuj GaggarRobert P MyersDiana M BrainardRichard ChildsTimothy FlaniganPublished in: The New England journal of medicine (2020)
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).
Keyphrases
- end stage renal disease
- newly diagnosed
- coronavirus disease
- ejection fraction
- sars cov
- placebo controlled
- chronic kidney disease
- double blind
- peritoneal dialysis
- prognostic factors
- stem cells
- clinical trial
- open label
- randomized controlled trial
- radiation therapy
- mesenchymal stem cells
- rectal cancer
- locally advanced
- smoking cessation